The QualityStocks Daily Thursday, July 8th, 2021

Today's Top 3 Investment Newsletters

MarketClub Analysis(NEGG) $67.57 +148.42%

InvestorBrandNetwork(PBIO) $4.01 +68.49%

QualityStocks(BSPK) $0.0215 +53.57%

The QualityStocks Daily Stock List

Second Sight Medical Products (EYES)

QualityStocks, PennyStocks24, MarketClub Analysis, INO.com Market Report, The Best Newsletters, Hit and Run Candle Sticks, INO Market Report, BUYINS.NET, TraderPower, Investment House, StockMarketWatch, InvestorPlace, Schaeffer's, Street Insider, StreetInsider, Jason Bond, Market FN, TradersPro, Marketbeat.com, InvestorsUnderground, MarketBeat, Investopedia, Money Morning, OTCtipReporter, Penny Pick Finders, PennyStockScholar, Weekly Wizards, Profitable Trader Authority, Rick Saddler, Stock Beast, The Street, Top Pros' Top Picks, Wealth Insider Alert, WealthMakers and PennyStockProphet reported earlier on Second Sight Medical Products (EYES), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in Sylmar, California and was incorporated in 1998 by Gunnar Bjorg, Robert J. Greenberg, Sam Williams, Aaron Mendelsohn and Alfred E. Mann. It operates as part of the medical equipment and supplies manufacturing industry under the health care sector in the medical equipment and devices sub-industry and serves consumers in the U.S.

The company’s objective is to allow blind individuals to achieve greater independence through their visual prosthetics. It operates in the geographical regions of China, Italy and the U.S. and derives the majority of its revenue from the U.S. The company’s Argus II retinal prosthesis system, which is made up of both external and implant components, brings in a lot of revenue.

The enterprise’s Argus II system electrically stimulates the retina in order to induce visual perception in blind individuals. This is in addition to treating outer retinal degenerations like retinitis pigmentosa. The enterprise also develops an implanted cortical stimulation device known as the Orion Visual Cortical Prosthesis System, which offers useful artificial vision to people who are blind because of eye injuries, optic nerve diseases or injuries, diabetic retinopathy and glaucoma, among other causes.

The company recently announced the closing of its public offering of 11,500,000 shares of its common stock. It revealed that it would be using these funds to further develop its Orion device, a strategic investment which will no doubt bring hefty returns to the firm and increase investments as well.

Second Sight Medical Products (EYES), closed Thursday’s trading session at $4.19, up 0.721154%, on 2,123,732 volume. The average volume for the last 3 months is 5.864M and the stock's 52-week low/high is $0.690599977/$20.00.

DiaMedica Therapeutics (DMAC)

MarketBeat, TradersPro, StockMarketWatch, StreetInsider, QualityStocks, Schaeffer's and BUYINS.NET reported earlier on DiaMedica Therapeutics (DMAC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in Minneapolis, Minnesota and was incorporated in 2000, on January 21st by Wayne Lautt. Prior to its name change in December 2016, the firm was known as DiaMedica Inc. It operates as part of the scientific research and development services industry under the health care sector in the biotech and pharma sub-industry. The firm serves consumers in Canada and the U.S. and has three companies in its corporate family.

The company is focused on developing treatments for clinically unmet needs or where no treatments are available, its main focus being on acute ischemic stroke and chronic kidney disease.

The enterprise’s product pipeline is made of a recombinant human tissue kallikrein-1 protein dubbed DM199, which concluded phase 2b REMEDY trial evaluating its efficacy in treating patients with acute ischemic stroke as well as phase 1b clinical trials evaluating its effectiveness in treating patients with severe or moderate chronic kidney disease caused by Type II or I diabetes. The DM199 formulation has also been indicated for the treatment of vascular dementia. The enterprise is working on advancing its kallikrein-1 recombinant into clinical testing to evaluate its efficacy in treating stroke.

The company recently revealed that the FDA had approved its Investigational New Drug Application for its DM199 formulation, which brings it one step closer to providing a much needed treatment option for individuals who experience acute ischemic stroke each year. The success of the formulation will not only be beneficial to patients but will also bring in more investments into the firm.

DiaMedica Therapeutics (DMAC), closed Thursday’s trading session at $4.13, off by 1.9002%, on 243,548 volume. The average volume for the last 3 months is 252,382 and the stock's 52-week low/high is $3.71000003/$10.8800001.

Biocept (BIOC)

plrinvest, RedChip, BUYINS.NET, MarketBeat, StockMarketWatch, INO.com Market Report, Marketbeat.com, TraderPower, MarketClub Analysis, Jason Bond, StreetInsider, QualityStocks, SmallCapVoice, PoliticsAndMyPortfolio, Promotion Stock Secrets, The Street, SmallCapNetwork, PennyPro, Trading Concepts, TradersPro, Top Pros' Top Picks, Joseph Green, Schaeffer's, StreetAuthority Daily, StockOodles, Stock News Now, smartOTC, Weekly Wizards, Red Bull Stocks, AwesomeStocks and The Online Investor reported earlier on Biocept (BIOC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in San Diego, California and was incorporated in 1997, on May 12th. It operates in the health care sector, under the biotech and pharma sub-industry and serves consumers and patients in California.

The company is party to a partnership agreement with CLEARED4 which entails the development of a system for managing and tracking coronavirus test results and testing requirements for its consumers. It markets its research and clinical trial services to clinical research organizations, biopharmaceutical firms and pharmaceutical firms, and sells its cancer diagnostic assays to oncologists and other physicians directly, at cancer centers, labs, hospitals and group and private practices in the U.S.

The enterprise’s cancer assays offer information to healthcare providers to identify alterations that qualify cancer patients for targeted therapy. Its assays for solid tumor indications include ovarian cancer, pancreatic cancer, melanoma, prostate cancer, colorectal cancer, gastric cancer, non-small cell lung cancer and breast cancer. The enterprise also provides lab services to pathologists, pulmonologists, urologists, surgical oncologists, neuro-oncologists and medical oncologists, as well as other physicians.

The firm was recently awarded a patent by South Korea for its Primer-switch technology, which identifies rare mutations in circulating tumor DNA through the use of real-time PCR. The product’s methodology adds to the company’s Target Selector assays, which help in physician decision-making. This move strengthens confidence in the company as well as its portfolio, which may trigger investor interest and bring more funds into the firm.

Biocept (BIOC), closed Thursday’s trading session at $3.87, off by 3.7313%, on 234,945 volume. The average volume for the last 3 months is 370,796 and the stock's 52-week low/high is $3.46000003/$13.00.

Powerbridge Technologies Co. (PBTS)

QualityStocks, StockMarketWatch, MarketBeat and StreetInsider reported earlier on Powerbridge Technologies Co. (PBTS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in Zhuhai, the People’s Republic of China and was incorporated in 1997 by Shiang Stewart Lor and Ben B. Lor. It operates in the technology sector, under the software and tech services industry in the software sub-industry and serves government and corporate customers across the globe.

The company sells its services and solutions via strategic government partners, indirect channel partners and direct sales organization and serves logistics service providers, government authorities and agencies and international trade manufacturers and businesses. The company generates its revenue in the form of subscription services, technical support and consulting services and application development services. All the company’s revenue is generated from China.

The enterprise provides insurance and export & import loan processing for consumers to streamline their regulatory compliance, trade logistics and trade operations as well as system solutions, including trade compliance and trade enterprise. It also offers Powerbridge Blockchain-as-a-service, which is made up of supply chain blockchain services and compliance blockchain services; and Powerbridge Software-as-a-service solutions, which comprises of Insurance and export & import loan processing service cloud, cross-border ecommerce cloud, inward processed manufacturing cloud, trade one operations cloud and logistics service cloud.

The company recently initiated its Smart City Operation Platform which the firm believes will play a key role in the digitalization of cities in China. The move helps to extend the company’s reach, which will in turn, boost its growth.

Powerbridge Technologies Co. (PBTS), closed Thursday’s trading session at $2.36, off by 5.2209%, on 2,781,908 volume. The average volume for the last 3 months is 2.942M and the stock's 52-week low/high is $1.07000005/$9.64999961.

Qumu Corporation (QUMU)

StockMarketWatch, StreetInsider, MarketBeat, TradersPro, TopPennyStockMovers, StockRockandRoll, PennyStockLocks, Penny Stock 101, Marketbeat.com, Trading Concepts, TraderPower, QualityStocks and Barchart reported earlier on Qumu Corporation (QUMU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in Minneapolis, Minnesota and was incorporated in 1978. Prior to its name change in September 2013, the firm was known as Rimage Corporation. It operates as part of the computer software industry under the technology sector in the software sub-industry. The firm serves consumers across the globe and has twenty companies in its corporate family.

The company operates in the following geographical segments: Asia, Europe and North America and generates most of revenue from North America. It serves the healthcare and biotech, technology and telecom, services and consulting, manufacturing, insurance and finance and banking markets as well as government customers, via channel partners and direct sales.

The enterprise platform offers video capture and video content management services which include add-ons, extensions, speech search, security and access control, automated workflows, and analytics as well as creation and editing. The platform also allows organizations to modernize their workplace by offering a more effective way to share data, grow access to videos and increase employee engagement. This is in addition to providing term software on a license basis, cloud-hosted software as a service and software on a license, as well as professional, support and maintenance services. The enterprise is also involved in the sale of 3rd party hardware appliances.

The firm recently released its preliminary financial results for the 2nd quarter of 2021, with its CEO noting that the firm was focused on developing its SaaS subscription business which plays a significant role in the company’s growth.

Qumu Corporation (QUMU), closed Thursday’s trading session at $2.83, off by 5.3512%, on 526,556 volume. The average volume for the last 3 months is 366,266 and the stock's 52-week low/high is $2.61999988/$10.50.

Twin Vee PowerCats, Inc. (TVPC)

We reported earlier on Twin Vee PowerCats, Inc. (TVPC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Company was formerly known as ValueRich, Inc. It changed its name to Twin Vee PowerCats, Inc. in April of 2016. Twin Vee PowerCats is based in Fort Pierce, Florida and the Company lists on the OTC Markets.

Twin Vee PowerCats manufactures American-made products with American marine craftsmen in an American factory. An experienced workforce in Fort Pierce hand-builds Twin Vee boats. Twin Vee PowerCats regularly makes substantial investments into new technology. This augments its traditional hand-built process.

Twin Vee PowerCats recently began redesigning new boat models to ensure that potential boat buyers give twin-hulled boats a chance. Among the re-imagined boats it has developed, Twin Vee launched the 24-foot center console power catamaran in 2019 to enthusiastic acclaim. Center Console Life showcases the boat in its review. Furthermore, Twin Vee PowerCats’ 240 CC was featured by Florida Sportsman Magazine in 2019, stating that the "model certainly hits the mark for style points along with fishability."

Twin Vee PowerCats also announced that because of the unprecedented state of the world because of the COVID-19 (Coronavirus) pandemic, Twin Vee's Management Team is monitoring developments in Florida and the country as a whole.

Mr. Joseph Visconti, President of Twin Vee PowerCats, said, "We want to assure our customers that we are 100 percent on top of this unfortunate situation. We will continue to follow the Center for Disease Control and Prevention for updates and observe any and all prescribed measures for the safety of our employees and the community at large."

Twin Vee PowerCats, Inc. (TVPC), closed Thursday’s trading session at $0.2899, up 41.4146%, on 37,953 volume. The average volume for the last 3 months is 19,806 and the stock's 52-week low/high is $0.018999999/$0.579999983.

Kalytera Therapeutics, Inc. (KALTF)

We reported earlier on Kalytera Therapeutics, Inc. (KALTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kalytera Therapeutics is also developing a new class of proprietary cannabidiol (CBD) therapeutics. Its intention is to explore the use of CBD, a non-psychoactive cannabis constituent. The Company is working to advance a portfolio of synthetic, non-psychoactive cannabis-like molecules. Additionally, Kalytera will center on orphan conditions, with the aim of generating data in humans that may support follow-on studies in major conditions.

Kalytera received approval from the Institutional Review Board (IRB) at one of two clinical sites in Israel. This is to begin a Phase 2 study to evaluate cannabidiol (CBD) for the prevention of GvHD. The proposed study is a Phase 2, open label, multicenter trial. The trial is to evaluate the pharmacokinetic profile, safety, and efficacy of numerous doses of CBD for the prevention of GvHD following allogeneic hematopoietic cell transplantation (HCT). The proposed study will take place at the Rabin Medical Center, Beilinson, and the Rambam Health Care Campus, Haifa, in Israel.

The expectation is that Kalytera’s continuing Phase 2b clinical study evaluating the use of CBD in the prevention of GVHD will be completed early this year. Upon completion of the Phase 2b clinical study, Kalytera will begin preparations for the pivotal Phase 3 clinical study that will be required for Food and Drug Administration (FDA) approval.

The work that Kalytera Therapeutics is doing in GVHD consists of two separate product development programs. One is a program evaluating CBD for the prevention of acute GVHD. A separate program is evaluating CBD for the treatment of acute GVHD. The Company’s program in prevention of acute GVHD is more advanced than is the program in treatment of acute GVHD.

Kalytera Therapeutics is the exclusive licensee of two issued U.S. patents covering the use of CBD in the prevention and treatment of GVHD. It is also the exclusive licensee of pending patent applications in other jurisdictions for the use of CBD in the prevention and treatment of GVHD.

Kalytera Therapeutics, Inc. (KALTF), closed Thursday’s trading session at $0.0239, up 25.7895%, on 118,671 volume. The average volume for the last 3 months is 296,968 and the stock's 52-week low/high is $0.000037999/$0.100000001.

HCi Viocare (VICA)

QualityStocks, ProTrader, Stock Commander, Shiznit Stocks, Penny Stock General, MicroCapDaily, OTCtipReporter, Penny Pick Finders, KingPennyStocks, Insider Financial, AwesomeStocks, HotOTC, PennyStockProphet, PennyStockScholar, StockWireNews, Small Cap Firm, Fierce Analyst, Stock Guru, Buzz Stocks, StockOnion, BullFreak, StockRunway, Profitable Trader Authority, BeatPennyStocks, Damn Good Penny Picks, Fortune Stock Alerts, Broad Street, MegaPennyStocks, OTCBB Journal, OTCMagic, Penny Picks, Penny Stock 101, PennyStockLocks, Today's Stock Tip, SmallCapGrowth, Stock Beast, StockHideout, StockRockandRoll, StocksImpossible, StockStreetWire and PennyPickAlerts reported earlier on HCi Viocare (VICA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HCi Viocare has two fully owned subsidiaries. One is HCi Viocare Technologies. The other is HCi Viocare Clinics. HCi Viocare Technologies is developing hardware solutions aiming to empower the user through providing on demand information and enhancing living quality.

HCi Viocare’s business model consists of creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and developing an extensive portfolio of proprietary hardware solutions with first in line the Flexisense™ sensor system. The clinics will provide independent and personalized quality of care for its patients. The first HCi Viocare clinic has been operating since September 2015 in Glasgow.  

The R&D center is working on a large portfolio of progressive, cutting-edge, and disruptive technologies in the Digital Health, Prosthetics, and Orthotics, Diabetes, Assistive Devices and Sports & Wellbeing fields. HCi Viocare has developed a unique sensing technology with the brand name Flexisense™. 

Flexisense™ technology is the next generation of sensing technologies for wearable devices. Flexisense™ is an inventive sensing technology. It measures pressure and shear forces. In addition, it provides on demand information wirelessly. Flexisense can be incorporated in a wide array of applications.  

The Company has developed a new application for its sensing technology Flexisense™, now for automotive tires. Flexisense™ applied to tires can monitor, in real time, tire deformation and actual traction between the tire and the ground.

HCi Viocare Management, acknowledging the great advantages of Blockchain technology, has decided to develop its own proprietary Blockchain based system for handling the sensitive client records in its Scottish Clinics subsidiary. This team will develop a proprietary Blockchain based system for handling and storing the data produced from the medical applications of its Flexisense™ technology.

HCi Viocare (VICA), closed Thursday’s trading session at $0.05, up 19.0476%, on 424,500 volume. The average volume for the last 3 months is 351,190 and the stock's 52-week low/high is $0.020999999/$0.395999997.

Aerpio Pharmaceuticals (ARPO)

QualityStocks, Zacks, TradersPro, MarketBeat, BUYINS.NET and StockMarketWatch reported earlier on Aerpio Pharmaceuticals (ARPO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in Cincinnati, Ohio and was incorporated in 2007, on November 16th by Joseph H. Garder. It operates as part of the pharmaceutical manufacturing industry and serves consumers in the United States.

The company was created to allow for the rapid development of more compounds and is managed by the same team that manages Akebia Therapeutics, who use an outsourced approach to pharmaceutical development. Both companies were founded by Joseph H. Garder. It is party to a collaboration and license agreement with Gossamer Bio Inc. which entails developing and commercializing GB004, a candidate indicated for the treatment of inflammatory bowel disease.

The firm’s product pipeline is made up of razuprotafib, or AKB-978, which recently concluded a phase 2 clinical trial to test its effectiveness in treating diabetic retinopathy and another phase 2 clinical trial treating ocular hypertension/open angle glaucoma patients. It also develops a monoclonal antibody currently in preclinical development, which has been developed to treat diabetic vascular complications, including diabetic macular edema and nephropathy, dubbed ARP-1536. In addition, the firm also develops a selective stabilizer indicated for treating inflammatory bowel disease, termed AKB-4924.

The company recently entered into a definitive merger agreement with Aadi Biosciences and they will focus on advancing the latter’s lead candidate ABI-009. This move will greatly benefit Aerpio Pharmaceuticals shareholders while also offering medical benefit to patients with advanced malignant PEComa.

Aerpio Pharmaceuticals (ARPO), closed Thursday’s trading session at $2.79, up 63.1579%, on 245,827,697 volume. The average volume for the last 3 months is 5.707M and the stock's 52-week low/high is $0.954100012/$3.31999993.

Unrivaled Brands, Inc. (UNRV)

SmallCapVoice, PennyStocks24, QualityStocks, InvestorPlace, MarketBeat, Promotion Stock Secrets, FeedBlitz, The Green Baron, OTC Stock Review, Jet-Life Penny Stocks, PennyPro, The Street, OTPicks, Greenbackers, Stock Beast, AllPennyStocks, PhD-Trading, OTCMagic, Marketbeat.com, Market Authority, CFN Media Group, StockHideout, HoleinOneStocks.net, Shiznit Stocks, Liquid Pennies, SmallCapReview, Whisper from Wall Street, HEROSTOCKS, Cannabis Financial Network News, Pumps and Dumps, Otcstockexchange, Stock Roach, Market Intelligence Center Alert, Penny Stock Buzz, Stock Brain, Penny Stocks Profile, Jason Bond, OTCPicks, Stock News Now, PennyStockSpy, VIP STOCK ALERTS, Top Gun, INO.com Market Report, PennyStockPickAlert, Stockgoodies, Winston Small Cap, Stockhunter.us, The Stock Psycho, TheMicrocapNews, StreetAuthority Daily, MarketWatch, Microcapmillionaires, MonsterStocksPicks, OTC Markets Group, Center Stage Stocks, OTCJournal, BestOtc, Beacon Equity Research, ActiveMarketReport, PenniesPicks, Penny Dreamers, Penny Stock, Bold Stocks, Laissez Faire Today, Insider Wealth Alert, Information Solutions Group, HotStockProfits, Hot Stock Profits, Investors Alley, InvestorSoup, CRWEFinance, Fast Money Alerts, Club Penny Stocks Network, DrStockPick, Liquid Tycoon, DreamTeamNetwork, Daily Wealth, CRWEWallStreet, CRWEPicks, Investopedia, Goldman Small Cap Research, The Stock Enthusiast, Stock Stars, Stock Twiter, StockBomb.com, StockGuru, StockHotTips, StockLockandLoad, Stockoutlaws, StockRockandRoll, StockRunway, Stocks That Move, Super Hot Penny Stocks, PennyStockMoneyTrain, SuperStockTips, SmallCap Network, The Stock Scout, The Trading Report, TheTradingReport, TooNiceStocks, Top Stock Picks, TopPennyStockMovers, Wallstreet Profiler, WallstreetSurfers, Wealth Insider Alert, WePickPennyStocks, Winning Penny Stock Picks, Super Nova Stock Picks, PennyStocks Forever, Penny Stock Finder, Penny Stock Heroes, Penny Stock Pros, Penny Stock Rain, Pennybuster, PennyDoctor, PennyOmega, PennyStockClub, PennyStockLocks.com, 007 Stock Chat, PennyStockPickReport, Stock Shock and Awe, PennyStockPlayers, Stock Preacher, PennyToBuck, PennyTrader Publisher, PoliticsAndMyPortfolio, Preferred Penny Stocks, PureActionStocks, Purely Penny Stocks, Real Pennies, RedChip, ShazamStocks, SizzlingStockPicks, SmallCap Fortunes, Penny Stock Craze and Wyatt Investment Research reported earlier on Unrivaled Brands, Inc. (UNRV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Unrivaled Brands is a vertically integrated cannabis-focused agriculture company. It operates through numerous subsidiary businesses. These include Blüm, IVXX Inc., Edible Garden, and MediFarm LLC. Unrivaled Brands’ commitment is to cultivate and provide the highest quality medical cannabis and other agricultural products. Listed on the OTCQX, Unrivaled Brands is based in Irvine, California.

Unrivaled Brands is integrating the best of the natural world with technology to create sustainable solutions for medical cannabis production, extraction and distribution, plant science research and development, food production, and Closed Environment Agriculture (CEA).

IVXX, Inc. is a wholly-owned subsidiary of Unrivaled Brands. IVXX produces cannabis-extracted products for regulated medical cannabis dispensaries throughout California and medical and adult-use dispensaries in the State of Nevada.

Unrivaled Brands has its wholly-owned subsidiary Edible Garden. It cultivates a premier brand of local and sustainably grown hydroponic produce. It sells via major grocery stores. In New Jersey, construction is taking place for a major new pack house to distribute salads and leafy greens for Edible Garden.

Unrivaled Brands' MediFarm LLC subsidiaries focus on medical and adult-use cannabis cultivation. Additionally, MediFarm subsidiaries focus on permitting businesses throughout Nevada.

Blüm offers a broad selection of cannabis products. These include flowers, concentrates, and edibles through its Oakland, California and many Nevada locations.

Unrivaled Brands, Inc. (UNRV), closed Thursday’s trading session at $0.32, up 16.8736%, on 652,162 volume. The stock's 52-week low/high is $0.059999998/$0.820200026.

Nocera, Inc. (NCRA)

QualityStocks, OTC Stock Review and Daily Trade Alert reported earlier on Nocera, Inc. (NCRA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Company’s first-generation RAS (Recirculating Aquaculture Systems) container system was introduced as a new and very simple way for local fish farmers to breed fish in Xing Yi, a city of Guizhou, China. In 2018, Nocera accomplished the development of its 2nd generation RAS cylindrical tank system. This system produces more than two times of fish harvest of container system per annum. Nocera has strategically partnered with CIMC to launch 4 new sites utilizing its 2nd generation RAS in Guizhou.

The Company’s Land-Based RAS can be used for saltwater and freshwater species. The RAS systems recycle water. In the process they help preserve the ecosystem through reducing pollution from an over concentration of fish in natural waterways or bodies. Nocera’s RAS tanks can produce up to 20,000-30,000 lbs. of fish annually.

Nocera’s plan is to expand its services outside of China, including Taiwan, the USA, Japan, and Thailand, through building its land-based RAS demonstration sites and fish farms. These promote the environmental benefits of its land-based RAS and let the public participate in its fish farming business. The Company manufactures RAS for saltwater and freshwater species. These include Tilapia, Perch, Bass, Crayfish, Crab, as well as Abalone.

Nocera previously announced the introduction of its next-generation of commercially operational Recirculating Aquaculture Systems (RAS) designed to improve productivity and sustainability in commercial aquaculture. The next-generation tank design features an improved oxygenation system that permits roughly 50 percent more fish to be raised in the tanks. Furthermore, it makes the transport of fish more convenient. At present, Nocera has its aquaculture equipment in Xing Yi, China and plans to install its next generation tanks in Taiwan.

Nocera, Inc. (NCRA), closed Thursday’s trading session at $4, up 21.5805%, on 600 volume. The average volume for the last 3 months is 300 and the stock's 52-week low/high is $2.02999997/$8.00.

Ascent Solar Technologies, Inc. (ASTI)

Profitable Trader Authority, Small Cap Firm, QualityStocks, OTCPicks, Investor Ideas, PennyStocks24, Alternative Energy, Top Stock Picks, SmarTrend Newsletters, StockEgg, StreetInsider, The Street, PennyTrader Publisher, DrStockPick, BestOtc, CRWEWallStreet, CRWEPicks, PennyToBuck, CRWEFinance, StockHotTips, PennyOmega, AllPennyStocks, Promotion Stock Secrets, PennyStockVille, PennyPro, MadPennyStocks, Penny Invest, CoolPennyStocks, BullRally, BUYINS.NET, HotOTC, Greenbackers, FeedBlitz, PennyInvest, Street Insider, SmallCapVoice, StockRich, StockOodles, Stock Rocket Report, TopPennyStockMovers, Stocks That Move, TheStockWizards.net, InvestorSoup, SuperStockHunter, SuperStockTips, The Momentum Traders Network, DSR News, InvestorsUnderground, The Stock Detective, TopStockAnalysts, TradingMarkets, Wall Street Resources, WealthMakers, Beacon Equity Research, Winston Small Cap, The Online Investor, Penny Stocks Finder, ProTrader, Wise Alerts, Shah's Insights & Indictments, Stock Market Authority, Stock News Now, Stock Preacher, Stock Specialists, MarketBeat, StockMister, Lebed.biz, Penny Stock Pinnacle, Penny Stock Craze, PCG Advisory, Momentum Traders, Rick Saddler, Mega Stock Picks, PHUB News and Stockgoodies reported earlier on Ascent Solar Technologies, Inc. (ASTI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Established in 2005, Ascent Solar Technologies is based in Thornton, Colorado, where its Research and Development (R&D) and its 30 MW nameplate production facility are. Ascent Solar modules were named as one of the top 100 technologies in both 2010 and 2015 by R&D Magazine. In addition, they were named one of TIME Magazine's 50 best inventions for 2011.

The Company is a developer of thin-film PV modules using flexible substrate materials that are more versatile and sturdy than traditional solar panels. The technology represents the leading edge of flexible power. It can be directly integrated into consumer products and off-grid applications, and also other aerospace applications. Ascent Solar Technologies provides solar solutions from bare modules to finished goods and everything in between.

The Company has its patented 3-step manufacturing process. Step 1 is thin-film deposition. Step 2 is monolithic integration. Step 3 is final assembly. Ascent’s inventive monolithic integration process enables the highest level of efficiency, durability and weight savings. This represents the potential to transform the way solar power can be used in everyday life. The Company’s solar technology and power solutions are for remote locations and extreme environments. Regarding its IP (Intellectual Property), Ascent Solar Technologies has more than 80 U.S. and International issued patents and published patent applications.

Ascent develops and manufactures its innovative CIGS (Copper-Indium-Gallium-Selenide) photovoltaic technology on a flexible, plastic substrate. The design of these panels are to convert sunlight into electric power through laying a thin layer of these four elements onto a plastic backing.

The Company is a leader in the CIGS field. It is the only manufacturer commercially producing CIGS solar on a plastic substrate with monolithic integration, which is an important differentiator for the Company.

Ascent Solar Technologies, Inc. (ASTI), closed Thursday’s trading session at $0.01785, up 26.5957%, on 94,249,004 volume. The average volume for the last 3 months is 51.619M and the stock's 52-week low/high is $0.000099999/$0.097000002.

The QualityStocks Company Corner

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX).

In June 2021, Lexaria Bioscience (NASDAQ: LEXX) announced positive results from its VIRAL-A20-2 study that evaluated the effectiveness of DehydraTECH-enabled remdesivir and ebastine among animals. The results were strongly positive and demonstrated greater effectiveness than in Lexaria’s first antiviral drug study reported in December 2000.

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 19 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday’s trading session at $6.7142, up 0.062593%, on 51,155 volume. The average volume for the last 3 months is 964,306 and the stock's 52-week low/high is $3.97510004/$9.46000003.

Recent News

Infobird Co., Ltd (NASDAQ: IFBD)

The QualityStocks Daily Newsletter would like to spotlight Infobird Co., Ltd (NASDAQ: IFBD).

As of 2019, the Chinese software-as-a-service SaaS market was estimated between $3.7 billion and $6 billion in value (https://ibn.fm/NBymg). That was just 6% less than the total value of the global SaaS market. This is great for the country. However, when compared to other nations such as the United States, the United Kingdom, Germany, Japan, South Korea, and India, it could use a little more adoption of SaaS and enjoy the benefits and growth that come with it. Infobird (NASDAQ: IFDB) seeks to address that, mainly through innovation and a marketing strategy meant to grow its market share and the SaaS industry in China.

Infobird Software (NASDAQ: IFBD), a software-as-a-service (“SaaS”) provider of AI-powered customer engagement solutions in China, offers holistic software solutions to support its growing corporate clientele deliver and manage customer engagement activities from beginning to end of the sales process; the company’s services even extend beyond to pre-sales and post-sales client support and involvement. Infobird combines its proprietary cloud computer structure with patented Voice over Internet Protocol (“VoIP”) and AI and machine learning capabilities as well as a no-code development platform for a flagship customer engagement offering unlike anything else in the industry. For more information, visit the company’s website at www.Infobird.com

Infobird Co., Ltd (NASDAQ: IFBD) is a software-as-a-service (SaaS) provider of AI-powered customer engagement solutions in China. Infobird leverages a self-developed cloud computing structure, AI and machine learning capabilities, patented Voice over Internet Protocol (VoIP) application technologies, a no-code development platform and in-depth industry expertise to best serve its growing client base.

Founded in October 2001, Infobird empowers clients with value-driven business solutions designed to increase revenue, reduce costs and enhance service quality and customer satisfaction. The company currently specializes in corporate clients in finance and a broad array of ancillary industries.

Infobird is headquartered in Beijing, China, and began trading on the Nasdaq Capital Market on April 20, 2021, following an initial public offering of 6.25 million ordinary shares at a public offering price of $4.00 per share, before underwriting discounts and commissions.

Product Offering

Infobird’s flagship customer engagement software can handle both AI Customer Engagement and AI Salesforce Management.

  • AI Customer Engagement
    • Intelligent Omni-Channel Customer Service – This offering allows clients to connect with their customers anytime and anywhere through a comprehensive suite of cloud-based tools.
    • Cloud Call Center – This service puts Infobird’s years of technical and operational experience to work for clients, with options including intelligent IVR technology, call monitoring, routing strategy and ticketing systems, all supported by multi-dimensional data reports.
    • Intelligent Telemarketing – Infobird’s AI bots can help clients navigate “never-ending lists” of potential customers, filter out the most promising leads and increase the working efficiency of agents, keeping agents focused on high-value tasks.
    • AI Voice Chatbot and AI Text Chatbot – This technology allows clients to create human-like interactions offering 24/7 availability and multi-round dialogue capabilities, decreasing labor costs by up to 80% while greatly improving efficiency.
  • AI Salesforce Management
    • Intelligent Quality Inspection – Infobird’s platform aims to improve quality inspection rates and service levels through the use of real-time smart monitoring with comprehensive coverage.
    • Intelligent Training – Interactive training programs allow clients to ensure and continuously improve the performance level of their agents, lessening the impact of high turnover rates common throughout the customer service industry.

Infobird’s client base includes roughly 10,000 paid user accounts representing 358 customers in the industries of finance, education, public services, consumer products and health care – as reported on June 30, 2020.

Market Outlook

Cloud infrastructure services spending in China increased by 32% ($39.9 billion) in the fourth quarter of 2020. For all of 2020, total services grew to $142 billion, up from the reported $107 billion in 2019. This growth can be attributed to rising demand for cloud infrastructure over physical software solutions (https://ibn.fm/rHZUh). China is the second-largest market for cloud infrastructure solutions after the U.S., accounting for roughly 14% of the global industry.

Likewise, SaaS has demonstrated considerable growth potential in recent years. In 2020, the SaaS industry in China was valued at $3.3 billion, representing an increase of 43.5% over 2019, as companies continue to leverage artificial intelligence and Big Data technologies to increase efficiencies and promote expansion.

As one of the leading and longest standing providers of domestic SaaS solutions and with a comprehensive portfolio of intelligent, customizable and scalable solutions, Infobird is uniquely positioned to capitalize on the market’s expansion and resulting opportunities for corporate growth.

Management Team

Yimin Wu is the CEO and Founder of Infobird. He has served as the Chairman of the board of directors and Chief Executive Officer of the company since it was founded. From August 1990 to March 1993, Mr. Wu was a software engineer for the Software Center of Tsinghua University and was sent to the U.S. to co-develop the HP_UX operating system at HP Inc. From April 1993 to May 2000, he served as the general manager for Beijing Jing Zhou Computers Co. Ltd., a company responsible for marketing and developing interactive voice response systems. From July 2000 to October 2001, Mr. Wu was the general manager for Beijing Jing Zhou Rong Hua Internet Technology Co. Ltd, a company responsible for developing middleware for call center establishments. He received a bachelor’s degree and a master’s degree in computer sciences from Tsinghua University.

Hsiaochien Tseng is the EVP of Infobird and has held the title since January 2020. From March 2010 to September 2018, he served as a sales director for the Credit Card Center of China Guangfa Bank, where he was responsible for integrating and managing online and offline sales channels, establishing overall and regional sales strategies and creating training systems to increase the client base. From October 2018 to January 2020, Mr. Tseng served as SVP of Hua Tuo Digital Technology Group Co. Ltd., a financial information technology company. He received a bachelor’s degree in information management from Fu Jen Catholic University and a master’s degree in business administration from San Diego State University.

Chunhsiang Chen is the VP of Infobird, a position he has held since April 2012. From June 1990 to February 1993, he served as an advisory programmer of International Business Machine Corp. (IBM). During that time, he participated in the design and development of the Multiple Protocol Transport Network. From February 1993 to September 1996, Mr. Chen served as an associate professor in the Information Education Department of National Taiwan Normal University. He founded GenNet Technology Co. Ltd., an information technology company, in 1993 and served as the president until joining Infobird in 2012. Mr. Chen has a bachelor’s degree in computer sciences from the National Chiao Tung University and a master’s degree and doctoral degree in computer sciences from Northwestern University.

Lianfang Zhou is the CFO of Infobird and has been with the company for over 10 years. From September 2004 to July 2008, she served as the head of accounting at Beijing Saishuo Technology Co. Ltd., a software development company specializing in port services. From August 2008 to December 2009, Mrs. Zhou served as the head of accounting for Beijing Lianhe Lida Investment Co. Ltd., a property management services company. She holds an intermediate accounting qualification certificate issued by the Ministry of Finance of the PRC. Mrs. Zhou also has a bachelor’s degree in accounting from the Renmin University of China.

Infobird Co., Ltd (IFBD), closed Thursday’s trading session at $3.62, up 2.2599%, on 1,980,061 volume. The average volume for the last 3 months is 2.459M and the stock's 52-week low/high is $3.25/$11.25.

Recent News

Ideanomics Inc. (NASDAQ: IDEX)

The QualityStocks Daily Newsletter would like to spotlight Ideanomics Inc. (NASDAQ: IDEX).

  • Ideanomics (NASDAQ: IDEX) recently completed the acquisition of 100% of privately held US Hybrid, heralding entry into the burgeoning EV powertrain market that is expected to grow at a 16% CAGR between 2020 and 2027. US Hybrid manufactures and sells electric powertrain components and fuel cell engines for medium and heavy-duty municipality vehicles, commercial trucks, buses, and specialty cars. The company welcomes US Hybrid CEO Dr. Abas Goodarzi, Ph.D., PE, and his entire team, with the acquisition expected to bring synergistic benefits to the various companies under the Ideanomics Mobility umbrella. A recent article quoted Dr. Goodarzi as saying: “Ideanomics has emerged as a true powerhouse in the commercial EV sector with a synergistic ecosystem of technologies and solutions that covers the entire value chain of electrification. We look forward to leveraging that strength going forward.” To view the full article, visit https://ibn.fm/AXvMI.
  • Like most developed countries, Germany is scrambling to reduce its carbon emissions by replacing internal combustion engine vehicles with zero-emission electric vehicles (“EVs”). Specifically, Germany, which is home to some of the largest automakers in the world, would like to achieve net-zero emissions by 2040. Having an estimated 7-10 million battery electric vehicles (“BEVs”) on the roads by 2030 is integral to this goal. Unfortunately, German drivers aren’t as receptive to BEVs as the government and the young electric vehicle industry would like them to be. Companies such as Ideanomics Inc. (NASDAQ: IDEX) have stepped up to address similar concerns among motorists, particularly in North America. Such initiatives are likely to go a long way in assuaging the concerns of people and encouraging them to embrace electric mobility, which will bring the zero-emissions targets within reach.

Ideanomics Inc. (NASDAQ: IDEX) is a global company facilitating the adoption of commercial electric vehicles and supporting next-generation financial services and fintech products. Ideanomics is currently divided into two divisions – mobility and capital. These divisions provide shareholders with access to disruptive and high-growth opportunities.

The company expects 2021 to be another growth year after it raised approximately $400 million over the past six months. This funding has already been put to good use with acquisitions of Wireless Advanced Vehicle Electrification (WAVE) and Timios. With roughly $200 million still on the balance sheet, Ideanomics continues to look for new investments and acquisitions in revenue-based opportunities focused on EV and fintech businesses.

Founded in 2004, Ideanomics is headquartered in New York, New York, with additional offices in Hangzhou, Beijing and Qingdao, China. Its current operations span the United States, China, Ukraine and Malaysia.

Ideanomics Mobility

Ideanomics Mobility is focused on the EV market. The global commercial EV market was valued at $34.7 billion in 2018 and is expected to grow at a CAGR of 39.9% through 2022 to reach a total of $132.73 billion (https://ibn.fm/pPrf4). According to a survey by Grand View Research, the global EV charging infrastructure market is also expected to grow and reach $144.97 billion in 2028, expanding at a CAGR of 33.4% from 2021 to 2028.

This growth is expected to be driven by increased support of electric vehicles from the public, as well as the current U.S. administration, which has a goal of achieving a 100% clean-energy economy.

The Ideanomics Mobility unit consists of five companies:

  • Mobile Energy Global (MEG) – Wholly owned China-based service provider of the Sales-to-Finance-to-Charging (S2F2C) business model to assist commercial fleet operators on EV enablement. Recent sales include 2,000 units of D1, BYD’s custom electric ride-hailing vehicle.
  • Medici Motor Works – Wholly owned North America division. MMW will develop zero-emissions specialty vehicles, trucks, buses and vans for the North American market.
  • Wireless Advanced Vehicle Electrification (WAVE) – Wholly owned Utah-based commercial EV charging technology company with a specialized offering of in-ground wireless charging for commercial vehicles. WAVE’s chargers power the Antelope Valley Transportation Authority, the largest municipal EV bus system in the country. Its revenue for 2020 exceeded $7 million, and it boasts a robust pipeline for 2021 and beyond.
  • Treeletrik – Majority investment in Malaysian-based OEM will service a high-demand market – electric delivery mopeds. Treeletrik has obtained certifications in Thailand and Indonesia, with orders secured for 2021. Its North American marketing program is expected to commence in 2021. As a part of the ESG initiative, one tree will be planted for every unit sold.
  • Solectrac – Minority investment in California-based electric tractor company. Solectrac manufactures 100% electric tractors to benefit farmers, crops and the planet at a time when the agriculture market remains virtually unaddressed by EV solutions.
  • Silk EV – Minority investment in hyper car and performance car design company, which provides access to the high-end battery and charging technology development ecosystem.

Ideanomics is generating EV revenue from its Sales to Financing to Charging (S2F2C) business model, which features three operating areas:

  1. Vehicle and Battery Sales: Medici, Treeletrik and Solectrac cover three key market segments
  2. Financing, Leasing and Insurance: Offering financial services to fleet customers, commission delivery and origination fee-based revenue
  3. Charging and Energy Services: Offering charging as a service, battery swap programs and WAVE wireless charging products

Ideanomics Capital

Ideanomics Capital is focused on providing disruptive fintech solutions across the entire board of financial services, ranging from financial markets to digital securities and assets to mortgages and more. More mainstream institutions and a growing number of companies have increased their digital securities services, along with institutional investments boosting bitcoin and the emergence of favorable regulatory developments, creating ample opportunities for widespread adoption of financial technologies.

Additionally, the U.S. real estate industry is ripe for technologization, as it currently is fragmented, antiquated, opaque and largely untouched by tech innovation. However, the expanding market, with U.S. home sales expected to grow 21.9% in 2021, and the increased digitization of all business spaces are expected to promote a digital-first experience as the new industry standard this year and beyond (https://ibn.fm/DwsUv).

The Ideanomics Capital unit consists of five companies:

  • Timios – Wholly owned subsidiary bringing real estate into the 21st century by providing value-add, fee-based services addressing the title and closing process of home buying and mortgage transactions. Timios works to create transparency and efficiency within the market. Timios ended 2020 as a cash flow and EBITDA positive business.
  • The Delaware Board of Trade (DBOT) – Wholly owned FINRA-regulated ATS and broker dealer based in Delaware.
  • Liquefy – Minority investment bringing innovation to investment in real assets with blockchain technology by increasing efficiency in fractional ownership, lowering entry to investment barriers and unlocking liquidity in assets that were previously illiquid.
  • Technology Metals Market (TM2) – Minority investment in UK company delivering a direct investment and trading market for technology metals with a newly accessible technology metals asset class for inventory diversification. The traded metals are 100% backed by physical metals.
  • Intelligenta – Investment providing AI and machine learning solutions for financial institutions and regulators.

Management Team

Alf Poor is Ideanomics’ Chief Executive Officer. He is a client-focused and profit-driven executive who has a track record of success in rapidly growing technology companies and large, multi-national organizations. Mr. Poor’s expertise includes business planning, financing and creating and implementing corporate governance policies, as well as handling management across organizations. His specialization is working with cross-border and multi-national startups. Before taking the CEO role at Ideanomics, he was the CEO for Global Data Sentinel.

Conor McCarthy is the company’s Chief Financial Officer. He is a strategic and operationally oriented management-level professional. His extensive international experience is within the fintech, data science and advertising technology sectors. Mr. McCarthy has experience with public companies, PE, and VC-backed firms. His specializations are financial and management reporting, planning and analysis, financial modelling, performance metrics, KPIs, venture borrowing, Series A equity funding, ERP system implementation, international business operations, and acquisition due diligence and integration. Before joining Ideanomics, Mr. McCarthy most recently held a CFO position at OS33. Prior to that, he was CFO for Intent Media Inc.

Kate Lam is the company’s Managing Director of Financial Products. She is highly regarded for her fixed income capital marketing skills across Asia and the United States. Ms. Lam has over 25 years of experience in the financial markets industry, dealing with many asset classes and clients. Having spent a few years in the fintech startup industry, her skills bridge the gap between traditional financial assets and new technological innovations. She has held senior management positions at Bear Sterns, Deutsche Bank and Standard Chartered Bank.

Keith Byers is Ideanomics’ Senior Vice President of Operations. He has extensive experience managing strategic relationships with key clients and deepening the relationships through innovation and successful engagement strategies. Before Ideanomics, Mr. Byers was the Managing Partner and Head of Operations for Gain Theory. He has a Master of Arts – MA, Economics from Heriot-Watt University and a Master of Science – Economics from The University of Edinburgh.

Tony Sklar is the company’s Senior Vice President of Investor Relations. He is a communication strategist and has worked for multi-faceted companies with global operations. Mr. Sklar handles omni-channel distribution using intelligence platforms and data insights for strategic planning, international expansion and marketing channels. His specialties include project management with digital strategy and transformation, ICO, marketing, blockchain and strategic partnerships. In addition to his role with Ideanomics, he is also a board member for the Delaware Board of Trade and the host and senior technology reporter for Far From TV.

Ideanomics Inc. (IDEX), closed Thursday’s trading session at $2.61, up 4.4%, on 16,893,510 volume. The average volume for the last 3 months is 19.981M and the stock's 52-week low/high is $0.800000011/$5.5300002.

Recent News

Healthy Extracts Inc. (HYEX)

The QualityStocks Daily Newsletter would like to spotlight Healthy Extracts Inc. (HYEX).

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based products for heart and brain health, has unveiled a game-changing nutraceutical formulation: Ultimate Brain Nutrients ACTIVATE(TM) (“UBN”). According to the company, clinical studies indicate that the proprietary formulation naturally increases key brain activity by as much as 46%. Other results from studies show that ACTIVATE significantly improves human cognitive behavior and mental focus by activating areas of the brain that are key in attention, memory, mood and quick reaction times. HYEX has devoted more than two decades in research on the formulation, which included approximately 100 clinical studies on the key ingredients. ACTIVATE is based on the company’s proprietary, naturally derived Fuel4Thought(R) formulation, which contains no sugar and caffeine. To view the full press release, visit https://ibn.fm/QhVqI

Healthy Extracts Inc. (HYEX) Healthy Extracts Inc. (HYEX), through its growing portfolio of wholly owned subsidiaries, is engaged in the proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. The company’s focus is to advance its market positions in the broader health industry through the unique assets and operations of its science-based BergaMet North America and Ultimate Brain Nutrients (“UBN”) subsidiaries and to offer better lifestyles through superior health technology.

BergaMet North America

BergaMet NA is engaged in the sale and distribution of a full line of proprietary product formulations derived from the rare Citrus Bergamot SuperFruit™ called “bergamot.” Bergamot is native to Southern Italy and is naturally sourced and uniquely loaded with various antioxidant polyphenols. Thanks to this composition, bergamot supports and promotes overall wellness specific to cholesterol, cardiovascular and metabolic health with no known side effects.

BergaMet NA is the only Citrus Bergamot SuperFruit™ heart health supplement backed by 17 clinical studies. The BergaMet brand supplement boasts the highest quality and concentration of polyphenols and flavonoids available anywhere in the world. It is also the only bergamot supplement approved by the prestigious Accademia del Bergamotto of Italy. BergaMet NA is the only company authorized to manufacture, distribute and sell these products in the United States, Canada and Mexico.

Consumers are including the Citrus Bergamot SuperFruit™ in their everyday personal health programs. The clinically proven antioxidant provides benefits to tens of thousands of people daily.

The company’s line of products can be found at www.bergametna.com, through Amazon, other online retailers and in doctors’ offices throughout the United States.

The BergaMet Advantage

BergaMet has been studied in 17 published clinical trials which reported results of lower LDL cholesterol, higher HDL cholesterol, lower triglycerides, lower blood pressure, lower blood glucose, increased arterial function, improved liver function and is effective as a complement to statin use.

Cardiovascular disease is the number one cause of death in the U.S. and worldwide, claiming nearly 18 million lives each year accounting for 31% of all global deaths. In the U.S., statins are one of the most commonly prescribed medicines for cardiovascular disease. The Centers for Disease Control estimates that 28% of American women and men over the age of 40 take a statin to lower the amount of cholesterol in the blood.

Taking aim at this market for cardiovascular care, BergaMet NA continues to advance the awareness of its medical-grade supplements and separate its formulation from competitors.

BergaMet NA products contain 47% BPF (bergamot polyphenolic fraction), while its closest competitors have only 38%. The company’s increased dosages (600-675mg vs 500mg) and 47% BPF are clinically proven to be more effective in improving heart health and metabolic syndrome.

BergaMet Citrus Bergamot SuperFruit™ supplements:

  • Support healthy immune systems with powerful antioxidants and proprietary formulations.
  • Reduce cholesterol and support healthy glucose and blood pressure levels.
  • Are fully organic, vegan-friendly and dairy, gluten, soy and GMO-free.
  • Contain five key unique flavonoids that make up the most powerful 47% BPF (bergamot polyphenolic fraction) in the world, providing superior results compared to their competitors.
  • Have been clinically shown to increase arterial elasticity while reducing arterial and muscle inflammation.

Ultimate Brain Nutrients

Healthy Extracts’ Ultimate Brain Nutrients (“UBN”) subsidiary is a science-based company that develops unique, plant-based superior health technology neuro-products that improve brain health, including memory, cognition, focus and neuro-energy.

UBN’s KETONOMICS® proprietary formulations – targeting brain activity, focus, headache and cognitive behavior — provide multiple intellectual property license opportunities for monetizing the company’s portfolio.

License opportunities include multiple beverage formats, individual products, proprietary mixtures and other food platforms.

UBN has five unique formulation patents – one issued and four pending – targeting brain activity, focus, headache and cognitive behavior.

The UBN Advantage

UBN’s all-natural, sugar-free and caffeine-free proprietary formulations are the result of 20 years of scientific research and are positioned to provide consumer neuro-products that are natural brain solutions. UBN has filed for approval to the U.S. Food and Drug Administration (FDA) to make a Qualified Health Claim for its migraine formulation, tapping into consumer demands for healthy beverages that contribute to brain health, overall well-being and performance.

Over 50 million Americans consume unhealthy energy shots and drinks each day, while the neuro/energy market generates over $10 billion per year in revenue. Within this growing market, UBN is advancing its position to meet rising consumer demand for healthy, science-based options. The company’s KETONOMICS® proprietary formulations have been proven to naturally elevate brain energy and function, including memory, cognition and focus.

UBN’s KETONOMICS® supplementation has also been studied in sports physiology, with specific regard to its potential benefits for competitive performance and endurance.

Healthy Extracts Executive Team

Kevin “Duke” Pitts, Director, President and Chief Operating Officer

  • Started and built from the ground up two multi-million-dollar businesses, one of which grew into a Top 100 retailers in the U.S.
  • Unique management skills led to the development of successful teams for 35 years
  • Pioneered direct marketing for a Fortune 200 company, creating a 20% increase in targeted incremental sales
  • Founded Einstein’s Hemp, which developed and brought to market one of the only odorless and tasteless water-soluble CBD products in the world
  • Developed and implemented digital/guerrilla marketing strategies for public and private companies focused on long-term brand position and acquisition efforts
  • Specialized in customer relationship management (CRM) tools for creating the best customer experiences
  • Worked in publicly traded industries for 10 years, overseeing up to $20 million in annual marketing budgets

William “Bill” Bossung, Director, Chief Financial Officer

  • 35 years of diverse experience in corporate finance, insurance and accounting
  • 20 years of experience with IPOs focusing on audits, FINRA and SEC regulations
  • Specializes in the formation of capital raising over $100 million, recently raising $12 million for Splash Beverage
  • Specializes in upgrading penny stocks companies to the NYSE or Nasdaq
  • Involved in 30+ companies transitioning from private to public identities
  • Founded several companies, including BCF Technology Inc., which sold to Vertafore; managing partner at Bishop Equity Partners LLC; director at Splash Beverage Group; and director of finance at Chadmoore Wireless, where he licensed channels to Nextel for $162 million

Bill Croyle, Director, Private Investor and Accomplished Senior Executive

  • More than 40 years of success in the IT, energy, manufacturing, telecommunications, venture capital and finance industries
  • Broad expertise includes negotiating mergers and acquisitions, as well as service and delivery contracts
  • Formerly was a founder, owner or executive of EnTX Group; Impact Legacy Partners; FB Oilfield Special Tools; and Western Energy Advisors

Dr. Gerald Haase, Chief Medical Officer

  • Clinical professor of surgery at the University of Colorado, School of Medicine
  • Actively involved in medical research and clinical trials for 35 years
  • Received U-10 grant funding from the National Institutes of Health cooperative group clinical trials program, as well as U.S. Congressional funding for Cooperative Research and Development Agreements with the Department of Defense and NASA
  • Was chairman of the Department of Pediatric Surgery at Children’s Hospital Colorado; consultant surgeon to the Department of the Army; vice-chairman of the Children’s Cancer Group, a cooperative research consortium of the National Cancer Institute; on the National Board of Directors of the American Cancer Society; a senior member of the Commission on Cancer of the American College of Surgeons; and a member of the editorial board of The Annals of Surgical Oncology
  • Has published 180 scientific papers and is the inventor or co-inventor of 12 issued U.S. patents for micronutrient and phytonutrient therapy, with five pending patents
  • Recipient of clinical research grants and contracts funded at a several million-dollar cumulative level
  • Is an editorial reviewer for medical journals and a member of numerous professional societies, including the American Association for Cancer Research, International College of Surgeons, American Academy of Pediatrics, New York Academy of Sciences and American College of Physician Executives

Healthy Extracts Inc. (HYEX), closed Thursday’s trading session at $0.098, up 28.9474%, on 99,529 volume. The average volume for the last 3 months is 14,685 and the stock's 52-week low/high is $0.052000001/$0.100000001.

Recent News

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Asia Broadband (OTC: AABB), a resource company focused on the production, supply and sale of precious and base metals primarily to Asian markets, has been highlighted in a recent Benzinga article for making aggressive moves in the crypto world. The article called the company’s AABB Gold Token a “one-of-a-kind” because of its vertical integration of mine-to-token gold backing, which means that, unlike other gold-backed cryptos, AABB holds physical gold assets that back the token 100% from the mining production segment of its holding company. The article also noted that more than $1 million of tokens were sold in the first few weeks of launch with AABB planning the release of its proprietary crypto exchange in the next few months. To view the full article, visit https://ibn.fm/mZ70L

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Thursday’s trading session at $0.1329, up 24.2056%, on 42,821,735 volume. The average volume for the last 3 months is 22.227M and the stock's 52-week low/high is $0.0023/$0.658999979.

Recent News

DSG Global Inc. (OTCQB: DSGT)

The QualityStocks Daily Newsletter would like to spotlight DSG Global Inc. (DSGT).

DSG Global (OTCQB: DSGT), an emerging global technology company with an array of interconnecting businesses in rapidly growing market sectors, together with its automotive division, Imperium Motor Corp., today announced preparation of vehicles for sales from partners Skywell Auto and Jonway Automotive Group in the coming months. “The company is finally in a position, with increasing production and inventory, regular shipments and proper lines of credit with the various manufacturers to begin delivering vehicles on a grander scale,” said Rick Curtis, CEO of Imperium Motors. “The current backlog is being processed and the company anticipates deliveries to individuals, fleets, dealers and government agencies during the second half of the year.” To view the full press release, visit https://ibn.fm/XPQIp

DSG Global Inc. (OTCQB: DSGT) is an emerging global technology company with interconnecting businesses in fast growing market sectors. With roots in the golf industry, the company specializes in golf fleet management and is moving quickly into road-ready electric vehicles for delivery in the third quarter of 2021.

In 2019, the company secured exclusive North America distribution rights for Jonway Automobile Co. road-ready electric vehicles (EVs). Jonway, based in Zhejiang, China, began manufacturing new vehicles s in 2003 and today produces Electric powered Cars, Trucks, Vans, SUV’s, and Scooters. Jonway vehicles are exported to more than 80 countries and are built to comply with U.S. safety and environmental standards.

These vehicles are being sold via DSG’s wholly owned subsidiary, Imperium Motor Company (IMC). The move into consumer vehicles capitalizes on the company’s strength in the selection and distribution of EVs, the ability to work with large manufacturers and in application of proprietary technology unique to DSG. DSG’s advanced fleet tracking can be integrated into Jonway EVs to offer a customized scalable and integrated solution to meet the needs of small businesses and large enterprises.

The Future is Electric

With decades of EV experience in golf, including distribution of highly advanced carts, DSG recognized the huge chasm between consumer interest in acquiring road ready EVs versus current EV models’ lack of availability and affordability. As such, the company focused on becoming a distribution and EV brand management company unencumbered by the manufacturing process. The manufacturers take responsibility for building vehicles to DSG’s specifications and fulfillment of regulatory and licensing requirements.

DSG has also established a distribution agreement with Skywell New Energy Automobile Group Ltd., an Asian-based EV manufacturer. Skywell will supply DSG with SUV’s, Passenger Vans, Cargo Vans, Commercial Vehicles and Buses that will be fully certified for use in the United States.

Brands

Imperium Motor Company (IMC) seeks to transform the way the world drives by making greener transportation available to everyone. IMC is an EV sales and marketing company that distributes directly to consumers and through third party distributors, offering a wide variety of affordable vehicles equipped for the North American market. The company’s emphasis is on great design, a green mindset, performance and functionality. Its vehicles include 26 models of high-speed, mid-speed and low-speed electric vehicles including cars, trucks, SUVs, vans, buses and scooters.

Vantage Tag Systems (VTS) is a global leader in the design, manufacture, and marketing of fleet management solutions for the golf industry. VTS has developed the TAG suite of products that represents the industry’s first completely modular fleet management solution. The company’s patented analytics, mobile touch screen GPS units and electric golf carts are sold around the world through a network of established distributors and partnerships with notable brands in fleet and equipment manufacture. VTS solutions also have applications in managing commercial, agricultural, military and government fleets. VTS is a wholly owned subsidiary of DSG Global.

Market Outlook

The global EV market was valued at $273 billion in 2017, according to Fortune Business Insights, and is projected to exceed $987 billion by 2027, with a projected CAGR of 17.4 percent. The relative high manufacturing costs of EVs compared to gasoline-powered vehicles and the resulting higher sticker price to consumers are major obstacles to near term market adoption.

The global e-bike market is estimated to grow to $70 billion by 2027 from its current valuation of $41.1 billion. An estimated 130 million e-bikes are expected to be sold globally over the next two years. The U.S. imported approximately 600,000 e-bikes in 2020, according to the Light Electric Vehicle Association, and its analysts expect that number will grow substantially in 2021.

Management Team

Robert “Bob” Silzer is the CEO of DSG Global. He is a serial entrepreneur who turns technology ideas in high growth industries into profitable businesses. With roots in the golf industry, he founded Vantage Tag Systems in 2008. Vantage Tag Systems is now a DSG subsidiary specializing in GPS-enabled fleet management.

Zahir Loaiza is the interim CFO of DSG Global. She assumed the role in March 2021, after having previously served as the company’s Corporate Controller. Her diverse international experience includes working at a publicly traded mining company, several law firms and more in the U.S., Canada and South America. Prior to pursuing a career in corporate finance, she was the owner of two retail entities.

Rick Curtis is the president and COO of Imperium Motor Company, the automotive subsidiary of DSG Global. His 40-year background in the automotive industry includes manufacturing, vehicle distribution, parts distribution, service management, dealer development and executive management of dealer groups. Prior to joining Imperium, Mr. Curtis served as president of Mullen Technologies and grew the company into a world class provider of electric vehicles, battery technology and energy storage systems.

William “Bill” Rex is president of Imperium Motor’s EV Bus and Motor Home Division. He has more than 40 years’ experience at suppliers of buses/electric buses, motor homes, trucks, specialty vehicles and batteries. He is the founder of Rexhall Industries Inc., formerly a publicly traded manufacturer of RVs and distributor of buses and coaches. He previously served as president of THOR West, a subsidiary of THOR Industries that manufactures shuttle buses, and as president of BYD Coach and Bus.

Patrick J. Parenti is the SVP Global Sales at DSG subsidiary Vantage Tag Systems. He has nearly 30 years of experience in golf and golf course management. Prior to joining DSG in 2012, Mr. Parenti served for 10 years as SVP at ProLink Systems, a leading global provider of GPS golf-course management systems.

Clint Singer is Director of Engineering at Vantage Tag Systems. He has been a senior developer in the golf industry for more than 20 years and has an extensive background in GPS systems.

Daniel Price is Technical Operations Manager of DSG Global’s European Region, UK, South Africa. In addition to his background in mechanical and electronic engineering, he is an audio engineer, specializing in automotive audio and security. He has also worked with high end electronic security companies in the UK and previously owned an electronic security and CCTV company.

Steven Mueller is Operations Manager at Vantage Tag Systems. He worked in the global pulp and paper market for nine years, facilitating the global movement of thousands of tons of timber products annually. Additionally, he has a successful decades-long track record of managing operations and consulting for a wide range of retail businesses.

DSG Global Inc. (DSGT), closed Thursday’s trading session at $0.191, off by 0.520833%, on 813,537 volume. The average volume for the last 3 months is 976,012 and the stock's 52-week low/high is $0.0108/$1.51999998.

Recent News

RYAH Group Inc. (CSE: RYAH)

The QualityStocks Daily Newsletter would like to spotlight RYAH Group Inc. (CSE: RYAH).

The coronavirus pandemic forced many physicians to switch from in-person visits to telehealth in a bid to keep their patients safe and also prevent the virus from spreading. While this may have been a temporary solution for some, many herald it as the future, with one industry expert urging optometrists to continue utilizing the technology for their practices even as in-person visits resume. With companies such as RYAH Group Inc. (CSE: RYAH) coming up with software and devices intended to expedite the switch to remote health solutions, it won’t be long before telehealth is a norm in all sectors of the medical field.

RYAH Group Inc. (CSE: RYAH) is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and university research centers, for experimentation and treatment validation – significantly reducing variations in patient-related trials. RYAH unlocks data in the complete therapeutic plant lifecycle – from seed to consumption.

Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union, as well. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis.

Product Portfolio

The company’s current portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component and the mobile application. The product line currently includes a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.

RYAH Smart-Inhaler

The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and dosages, all of which can be customized to individual needs and doctor recommendations, as well as a post-session review mechanism that allows the collection of session data and feedback for further efficacy analysis for customized dosing capabilities.

RYAH’s proprietary stainless-steel cartridges for the inhaler use QR technology that contains lab testing and grower information pertaining to the specific strain, thereby mitigating elicit product use and enabling completely transparent remote medicinal analytics, from seed to consumption.

In addition, the RYAH Cartridges provide a unique closed-loop recurring revenue opportunity for the company, as the RYAH Inhaler only works with this type of proprietary cartridges that licensed partners fill with medicine. The partners benefit from all the back-end data, providing them access to consumption habits, statistics and other data on patient preferences.

RYAH Smart-Patch

The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and the heating element is completely IoT and controlled by RYAH’s proprietary smartphone applications, which allows scheduling and ‘boosting’ medicine release, on-demand.

RYAH Smart-Pen

The RYAH Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect’, enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. The Smart-Pen will feature cartridges that contain CBD, THC and other isolates such as flavonoids or vitamins, or other solutions. There is a built-in mechanism designed to control usage based on recommended dosing schedules.

RYAH MD

RYAH MD serves as a remote and interactive patient-doctor collaboration and dosing administration platform. Doctors can remotely set dosage amounts for their patients, creating digital prescriptions for the RYAH IoT devices and tracking patient usage in real-time. RYAH MD offers features that include real-time monitoring, appointment booking, doctor-patient video calls and science-based strain recommendations, as well as promoting a better understanding of the effects and benefits of those recommendations among patients. Information is gathered from all of the RYAH devices.

PotBot App

The PotBot App is a medical cannabis education mobile application that leverages patented AI technology to capture structured and unstructured data to assist patients in learning about various treatments in plant-medicine based on their efficacy goals. The PotBot App is currently one of the top-rated medical cannabis educational mobile applications on the Apple App Store in the United States, with over 300,000 downloads.

Through the combination of peer-reviewed and empirical data, the PotBot App provides detailed information on the targeted and tested cannabinoid levels and associated strains from cannabis patients. The result is personalized and driven by data to inform patients of potential product matches associated with similar ailments and efficacy goals.

Market Outlook

RYAH holds a unique position in the $100.3 billion medical plant market, with the potential to capture and capitalize on growth opportunities made available by both the IoT and Data Intelligence sectors.

In 2018, the global IoT market was valued at $212.1 billion, and it is expected to grow exponentially to $1.3 trillion by 2026, registering a CAGR of 25.68%, according to Verified Market Research (https://ibn.fm/XtkPZ).

Management Team

Dr. Boris Goldstein, Ph.D., is the founder and Chairman of RYAH Group. He is a seasoned entrepreneur, investment banker and venture capitalist. He started his career as the founder of Software House HT, which grew into a worldwide corporation with over 40 offices in 17 countries. Since then, Goldstein has founded and served on the boards of directors and advisory boards for numerous companies in Silicon Valley and Silicon Alley. Goldstein brings experience in fundamental research, investment and technology, authoring multiple patents and books.

Gregory Wagner, MBA, is Chief Executive Officer and Director of RYAH Group. He has over 20 years of experience in global financial markets and entrepreneurship. Wagner has held executive roles in the United States and London. He has co-founded and built several startups from the ground up. His current licensures and degrees include FINRA Series 7, 63, 24 and 55, as well as an MBA from Fordham University. Wagner received a Certification in Innovation and Strategy from Harvard University.

RYAH Group Inc. (CSE: RYAH), closed Thursday’s trading session at $0.70, off by 6.67%, on 719,360 volume. The average volume for the last 3 months is 794,915.

Recent News

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

  • As of 2020, the global biotech sector was valued at $753 billion. It is further projected to grow at a compound annual growth rate of 16% between 2021 and 2028 (https://ibn.fm/zidIe). Two key sub-sectors show great promise:  cannabis and psychedelics, which both have significant potential with drug development activities. This value is further evidenced by the recent growth in venture capital investment in these industries and the success of the industry pioneer, GW Pharma, which was acquired by Jazz Pharmaceuticals plc (NASDAQ: JAZZ) for $7.2 billion in February 2021 (https://ibn.fm/ia4Du). Between 2019 and 2020, venture capital investment in this sector grew from $100 million to $346 million. So far in 2021, the sector has raised over $329 million. Additionally, Jazz Pharmaceutical’s acquisition of GW Pharma serves as validation of a sector that has tremendous potential for growth while addressing conditions with few existing treatment options (https://ibn.fm/MwYsX). Like GW Pharma’s successful approach with cannabis-derived compounds, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is driving significant innovation with its drug development pipeline using psilocybin-based compounds for the treatment of diseases with high unmet medical needs through accelerated regulatory pathways.
  • In the last decade, a lot of clinical research on psychedelic substances has been conducted, with many scientists focusing on their use in treating psychological and mental ailments. This has also led to a surge in investments into psychedelic research, with many results heralding psychedelics as effective alternative medications for various ailments. The research above is by no means the only ongoing work on psychedelics. In fact, several companies, including Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), are also hard at work developing psychedelics formulations intended to treat conditions with underserved or unmet medical needs, particularly mental health disorders.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

  • Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
  • Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
  • Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

  • Increased efficacy
  • Natural blood-brain barrier penetration
  • Enhanced safety and toxicity profiles
  • Reduced risk of abuse
  • Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Thursday’s trading session at $0.3948, off by 0.16437%, on 74,256 volume. The average volume for the last 3 months is 77,242 and the stock's 52-week low/high is $0.370000004/$1.03999996.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

  • Mobile technology and marketing company Friendable (OTC: FDBL) continues to build value in the music streaming industry through the Fan Pass platform, which will mark its one-year anniversary on July 24, 2021. At that time, the company will release a new version of the platform for both desktop and mobile applications, equipped with new features, UI/UX design, and benefits for artists and fans alike.
  • Friendable (OTC: FDBL), a mobile technology and marketing company, today shared details surrounding the new features, services and performance upgrades of its Fan Pass Live platform, version 2.0. “Demand for digital entertainment continues to increase, and we are pleased to announce that we are seeing a greater number of artist sign-ups, fan support, merchandise sales and live performances through our current Fan Pass platform,” said Friendable CEO Robert A. Rositano Jr. “As we approach the one-year anniversary of the launch of Fan Pass Live, the time is rapidly approaching to unveil the full breadth of what our team has been developing over the past 10 months. It’s been rewarding to hear the feedback and see our team take action on each and every detail that supports our artists and their fans. This is what it’s all about, and v2.0 has everything we need to scale. I believe that’s exactly what our supporters will see coming in our next phase.” To view the full press release, visit https://ibn.fm/K3CLE

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Thursday’s trading session at $0.01, off by 2.9126%, on 2,877,429 volume. The average volume for the last 3 months is 2.93M and the stock's 52-week low/high is $0.007799999/$0.174999997.

Recent News

First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF)

The QualityStocks Daily Newsletter would like to spotlight First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF).

At the onset of the coronavirus pandemic in March 2020, metal prices declined significantly, prompted by a collapse in the demand for metals. Capital spending cuts in the mining sector and mine closures imposed to control the virus’ spread also disrupted both the long-and short-term supply of metals. Today the metals market is at an entirely different level with iron ore and copper prices hitting new highs. Cobalt and nickel metal prices reached two- and seven-year highs in February and March of this year. Government stimulus has aided in the growth in demand for metals and facilitated metal price recoveries. Analysts expect industrial metals, particularly cobalt, lithium, zinc, iron ore and copper, to peak in this quarter. This favorable outlook is likely to be an encouragement to extraction firms such as First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF) to press ahead with their exploration, development and extraction activities.

First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF) is a publicly traded Canadian mineral exploration company. Its primary focus is on developing a multi-commodity mineral property portfolio by identifying, acquiring and exploring North American mineral prospects in the precious metal, base metal and industrial metals sectors.

Headquartered in Vancouver, the company (formerly known as “Agave Silver”) was first incorporated on October 12, 1966.

Core Properties – Augustus Lithium and Titan Gold

Located in Landrienne & Lacorne-Townships, Quebec, Canada, in an active lithium exploration/mining area, the Augustus Lithium Property and surrounding claims total 14,367.71 hectares . It is equipped with excellent infrastructure support, including a road network, railway, electricity, water and trained manpower available locally.

Other highlights of the Augustus Lithium Property include:

  • Geologically similar to Sayona Mining’s Authier Lithium project and Mine Quebec Lithium project located 6-12 km away.
  • Documented historical drilling over 10,000m in 62 drill holes, worth over $2 million in present day exploration expenditures.
  • Two prominent lithium and one silver prospects located on the property.
  • A potential high grade lithium resource target of 4 million tonnes at 1% lithium oxide (Li2O).
  • Potential for large volume low grade bulk tonnage near surface.
  • Two phase exploration work program includes: data compilation, geological mapping, trenching and sampling in Phase 1 (estimated cost $191,418) and diamond drilling, metallurgical testing and resource estimation in Phase 2 (estimated cost $1,166,963).

The Titan Gold Property is located in the Detour-Fenlon Greenstone Belt of east-central Quebec and is comprised of 80 mining claims totaling 4,334 hectares.

Other highlights of the Titan Gold Property include:

  • The Detour-Fenlon Greenstone Belt is host to the Detour Mine containing 20 million ounces of gold. The Fenlon Project of Wallbridge Mining has also reported strong high-grade gold intercepts and a successful high-grade (18.49 g/t Au) bulk sample.
  • Hosted within a structurally active geological environment with several northwest trending deformation zones which are splays off the Sunday Lake Deformation Zone – all key ingredients to the gold mineralization in the area.
  • The property has seen little historical exploration yet sits within what is becoming a prolific recognized gold camp.

Non-Core Properties – Kokanee Creek Gold and Scramble Mine Properties

The Kokanee Creek Gold Property consists of three mineral claims covering approximately 1,590.29 hectares in the Nelson Mining Division in British Columbia.

Other highlights of the Kokanee Creek Gold Property include:

  • Gold mineralization indicated in surface samples from historical work since 1979.
  • Subsurface gold mineralization discovered in drill holes.
  • Continuity of mineralized zones indicated through geological mapping, geochemical and geophysical survey.
  • Past producing mines in the vicinity, including the Molly Gibson and the Alpine deposits.
  • Historical production reported for the Molly Gibson Mine from 1909-1940 was at an average grade of 36.1 g/t Au and 15.3 g/t silver, with recent exploration returning samples running up to 270 g/t Au.
  • Revived exploration on the Alpine deposit area has reported a 2018 inferred resource of 142,000 oz at 16.52 g/t Au using a cut-off grade of 5.0 g/t.

First Energy Metals also holds an option to acquire a 100% interest in the Scramble Mine Gold property, located approximately 8 km east of the town of Kenora in Northwestern Ontario. The mine was discovered in 1894 but remained essentially dormant until 1984, when Boise Cascade Canada Ltd. commenced an evaluation of the property. Since 1984, approximately 5,200 meters of diamond drilling, 250 meters of surface stripping with sampling and 450 meters of underground development have taken place at the property.

Other highlights of the Scramble Mine Property uncovered as part of the company’s 2020 prospecting and sampling programs include:

  • Average value of gold in surface samples is 29.34 grams per tonne (1.03 ounces per tonne).
  • Gold assays ranged from 5.03 grams per tonne (0.18 oz/t) to 82.30 grams per tonne (2.90 oz/t), with two samples assayed over 2 oz/t.
  • All samples assayed over 5 grams per tonne gold.

Market Outlook

The global precious metals market was valued at $193.3 billion in 2020 and is expected to grow at a CAGR of 9%, resulting in a market valuation of $362.1 billion by 2027 (https://ibn.fm/WvN9Z).

The global lithium metal market was valued at $534.6 million in 2020. Through 2027, it is expected to grow at a CAGR of 9.6%, resulting in a forecast valuation of $926.6 million (https://ibn.fm/xBXcx).

First Energy Metals is well positioned to leverage growth opportunities in these expanding sectors through exploration of both its core and non-core properties.

Management Team

Gurminder Sangha is the Chief Executive Officer and Director of First Energy Metals Ltd. He is experienced in the financial industry, focusing on providing advisory-level services to privately and publicly traded companies. Mr. Sangha brings over 18 years of diverse experience related to financial management, business leadership and corporate strategy to his role with First Energy Metals. During his tenure as a board member for various publicly traded companies, he has led initiatives related to corporate finance, business development and corporate governance. Mr. Sangha has an MBA from both Queens University and Cornell University.

Jurgen Wolf is the Chief Financial Officer and Corporate Secretary for First Energy Metals Ltd. He has been involved in the oil and gas industries for over 15 years, assisting public companies with administration and investor relations. Mr. Wolf was educated in Germany and immigrated to Canada in 1953. From 1958 to 1982, he owned and operated pre-cast concrete factories in Calgary and Vancouver. From 1982 to 2002, Mr. Wolf owned and operated J.A. Wolf Projects Ltd., a commercial construction company. He is the previous President and Director of the former US Oil and Gas Resources Inc., which amalgamated to form Petrichor Energy Inc. in 2005. Mr. Wolf retains director roles with several public companies.

First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF), closed Thursday’s trading session at $0.170193, off by 9.0849%, on 18,865 volume. The average volume for the last 3 months is 10,925 and the stock's 52-week low/high is $0.086999997/$0.45719999.

Recent News

Sanwire Corp. (SNWR)

The QualityStocks Daily Newsletter would like to spotlight Sanwire Corp. (SNWR).

Sanwire (OTC: SNWR), a diversified company with a focus on technologies for the entertainment industry, and its wholly owned subsidiary Intercept Music Inc. have announced a partnership with Tory "Flossy the Boss" Harrelson. According to the announcement, Harrelson will head business development for Intercept Music. With more than 20,000 followers on social media, Harrelson is highly regarded among artists, independent record labels and influencers and brings his impressive network of musicians, writers, labels and top music executives to his new position. He is well known for posting timely information about the industry as well as providing artists with relevant marketing tips and advice to help them find success in the music industry. To view the full press release, visit https://ibn.fm/o9NAG

Sanwire Corp. (SNWR) is a diversified company currently focused on technologies for the music industry. The company specializes in locating unique opportunities in fragmented markets and implementing its aggregated technologies to consolidate distinct services into unified platforms of delivery. Sanwire is currently focusing these efforts on advanced entertainment technologies.

Founded in 1997 and based out of Las Vegas, Nevada, Sanwire has operated and sold several subsidiaries as it has worked in various industry segments, including Sanwire Software Inc., Bullmoose Mines Ltd. and Squeeze Report Inc. Currently, there are two new holdings that were added to the company’s portfolio through two recent acquisitions, including Intercept Music Inc. in March 2020 and the Art is War Record Label in June 2020.

Intercept Music Inc. – Artist-Focused Services

Intercept Music Inc. is an entertainment technology company offering a unique suite of artist-focused services that are specifically designed to meet the needs of recording artists. Intercept’s proprietary online platform is dedicated to helping millions of global independent artists effectively promote their music and distribute it worldwide to hundreds of digital stores and every major streaming platform, including Spotify, Apple Music, Amazon Music, Pandora and Google Music.

With Intercept Music, recording artists have all the tools needed to market, promote and sell their music online and through social media. Comprehensive reporting allows artists to track the fan response to their releases, all the way down to individual music tracks.

There are three foundations of Intercept Music’s product offering:

  • Its music distribution platform that is well augmented via the company’s partnership with InGrooves, a wholly owned subsidiary of Universal Music, which is arguably one of the largest music companies in the world.
  • Its social media system, which is tailored to work the way artists use social media to promote their music and engage with their fans. The scheduling system integrates artists’ profiles across multiple social networking sites (Facebook, Twitter, Instagram and YouTube) to facilitate new audience sampling, fan development and the ability for music to be previewed and purchased.
  • The third is represented by the team of developers that brings a unique combination of deep technical expertise (in products like Skype), a team of well-accomplished executives and what the company calls Brand Ambassadors – senior reps from multiple genres who have helped artists earn over 100 Grammys.

Intercept Music is the confluence of technology and this music expertise.

The company currently markets three plans to its clients, with each offering different distribution and royalty options, as well as various marketing and reporting options. The plans are described below:

  • Intercept Distro is a basic plan for self-service music distribution with royalty collection. Artists keep 100% of the royalties while receiving unlimited releases and full analytics with reporting.
  • Intercept Artist includes all of the benefits of the basic Distro plan with added emphasis on social marketing and distribution for emerging artists. With this plan, artists receive scheduled and ad-hoc posting, social media reporting, reusable content libraries and access to other valuable features.
  • Intercept PLUS is available by invite only and is for established artists looking for a complete suite of marketing, distribution and monetization services. The PLUS plan includes everything available through the Distro and Artist plans, as well as offering a dedicated service representative, a branded online store, on-demand merchandise, additional marketing, YouTube monetization and other pro features.

Intercept PLUS is the flagship plan. Artists of this caliber often do $3-$10k/month in merchandise sales alone, at 50%+ profit. Intercept is responsible for marketing to the fan base through its social media system and shares in the profits generated. The stores are managed by intercept so both top-line revenues and bottom-line profits flow through Intercept.

Intercept Music has partnered with Ingrooves Music Group, the largest online music distribution company in the world, for worldwide distribution to streaming services and leading stores. Completing more than 50 billion transactions weekly across over 150 countries, Ingrooves supplies music to leading streaming music platforms and lists some of the world’s largest and most reputable music labels among its clients. The partnership allows Intercept Music and its clients to reach a much wider audience and start earning revenue as soon as possible by leveraging Ingrooves’ quality control systems and direct relationships with leading music streaming services.

Physical Distribution Options for Intercept Music Clients

In a press release on June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart (http://nnw.fm/NSrbE). The physical distribution will consist of CDs and vinyl and will serve as a supplement to the online streaming platform access provided by the company to represented artists.

“In the current climate, artists can’t play shows or otherwise engage in public at all, so they’re focusing on all other opportunities to bring in revenue,” Intercept Music President Tod Turner stated in a news release. “Our only priority is to help artists monetize music in every way, and with physical distribution added to the mix, we’re leaving no stone unturned in helping artists to earn money from their creative output.”

Creation of Preferred Stock

On June 29, 2020, Sanwire CEO Christopher Whitcomb announced that the company would be filing certificates of designation with the Nevada Secretary of State for its Series A, B and C preferred stock (http://nnw.fm/svrQt).

Speaking about this designation in a news release, Whitcomb stated, “Our paramount goal is to maintain a balanced approach between future investments and shareholder value while minimizing shareholder dilution. The effective utilization of preferred stock ensures our company can grow with the least amount of shareholder dilution.”

Sanwire is leveraging a multi-dimensional strategy that includes additional acquisitions, attracting investors and enhancing the current balance sheet while minimizing dilution for shareholders. A primary goal of these efforts is to support Intercept’s ongoing operations.

Financial Highlights

For the fiscal quarter ended June 30, 2020, Sanwire announced significant revenue growth related to the acquisitions of Intercept Music and Art is War Records. Since acquiring Intercept Music in March and Art is War Records in June, Sanwire’s revenue has increased by approximately 300% (http://nnw.fm/j0S0j). Sanwire attributes the increase in revenue to Intercept Music’s customer acquisition and the release of its PLUS plan.

For the third quarter, revenue is expected to continue an upward climb, owing largely to physical distribution plans and a rising number of PLUS subscribers. The company’s acquisition of Art is War Records is also expected to fuel this growth.

Management

Christopher M. Whitcomb is the current CEO of Sanwire Corp. and Intercept Music Inc. He is a CPA in the state of California, holding bachelor’s degrees in accounting, corporate finance and business management with a focus on real estate. A seasoned executive, his business ventures are always strongly focused on the development and financing of companies.

Whitcomb worked alongside Ralph Tashjian at SMC Entertainment Inc. and Digital Music Universe. They are currently working together again following Sanwire’s acquisition of Intercept Music, which was founded by Tashjian.

Sanwire Corp. (SNWR), closed Thursday’s trading session at $0.0062, off by 6.0606%, on 801,206 volume. The average volume for the last 3 months is 918,896 and the stock's 52-week low/high is $0.004999999/$0.048399999.

Recent News

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (OTC: SGMD).

Sugarmade (OTC: SGMD), an innovator in the dynamic California cannabis sector, is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real time to identify emerging desires and behaviors poised to unlock new pathways and opportunities for growth. “Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business — resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources,” reads a recent article discussing SGMD. “The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.” To view the full article, visit: https://cnw.fm/agVpe

Sugarmade, Inc. (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources.

The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.

Brand Portfolio

Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

  • NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
  • BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company

On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc.

The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total.

Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience.

“The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Market Opportunity

The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018.

Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020.

The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share.
Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward.

Management

Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Sugarmade, Inc. (OTC: SGMD), closed Thursday’s trading session at $0.0022, off by 4.3478%, on 160,130,835 volume. The average volume for the last 3 months is 126.222M and the stock's 52-week low/high is $0.000699999/$0.019999999.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading